Loading...
XNAS
ORKA
Market cap37mUSD
Dec 05, Last price  
30.84USD
1D
-0.29%
1Q
88.62%
IPO
20.94%
Name

ARCA Biopharma Inc

Chart & Performance

D1W1MN
XNAS:ORKA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
5.23%
Shrs. gr., 5y
66.27%
Rev. gr., 5y
%
Revenues
0k
545,0003,888,00046,861,00015,251,0000000000000000000
Net income
-84m
L+1,468.16%
-71,611,000-130,553,000-12,301,000-29,923,000-9,138,000-8,420,000-5,364,000-4,320,000-6,939,000-9,689,000-11,445,000-16,463,000-18,490,000-7,931,000-5,482,000-9,738,000-19,231,000-9,256,000-5,339,000-83,724,000
CFO
-58m
L+1,053.51%
-59,035,000-37,060,000-45,958,000-46,508,000-41,726,000-8,324,000-6,959,000-4,078,000-5,288,000-9,406,000-10,534,000-14,987,000-17,472,000-8,244,000-4,801,000-7,725,000-18,762,000-10,912,000-5,014,000-57,837,000
Dividend
Aug 29, 20241.613 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
URL
https://arcabio.com/
IPO date
Jul 21, 2000
Employees
5
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT